US2017137803A1PendingUtilityA1
Methods and compositions for synthetic rna endonucleases
Assignee: UNIV NORTH CAROLINA CHAPEL HILLPriority: Jun 18, 2010Filed: Nov 16, 2016Published: May 18, 2017
Est. expiryJun 18, 2030(~3.9 yrs left)· nominal 20-yr term from priority
C12N 9/22C12N 15/86C12N 15/102C12N 2750/14143A61K 38/465C12N 7/00G01N 2333/922G01N 2333/08Y02A50/30C12N 9/16C07K 2319/85C12Q 1/44
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.
Claims
exact text as granted — not AI-modified1 .- 42 . (canceled)
43 . A method of cleaving a target mRNA in a sample, comprising contacting the sample with a synthetic site-specific RNA endonuclease which comprises:
(i) an RNA binding protein domain that comprises a variant of the human Pumilio 1 homology domain, wherein said variant comprises eight 36-mer repeats, wherein each of the eight 36-mer repeats binds to a single nucleotide in an eight-nucleotide target RNA, wherein said eight-nucleotide target RNA comprises at least one cytosine, and wherein said variant comprises all of amino acids 828 to 1176 of SEQ ID NO:149 except for modifications at one or more positions corresponding to:
(a) positions 863 to 867 of SEQ ID NO:149,
(b) positions 899 to 903 of SEQ ID NO:149,
(c) positions 935 to 939 of SEQ ID NO:149,
(d) positions 971 to 975 of SEQ ID NO:149,
(e) positions 1007 to 1011 of SEQ ID NO:149,
(f) positions 1043 to 1047 of SEQ ID NO:149,
(g) positions 1079 to 1083 of SEQ ID NO:149, and/or
(h) positions 1122 to 1126 of SEQ ID NO:149,
wherein said modifications result in the variant comprising, in any combination, SerXXXGlu (SEQ ID NO:1) to bind guanine, (Cys/Ser)XXXGln (SEQ ID NO:66) to bind adenine, AsnXXXGln (SEQ ID NO:3) to bind uracil, and/or SerTyrXXArg (SEQ ID NO:4) to bind cytosine, wherein X is any amino acid;
(ii) a linker peptide; and
(iii) a cleavage domain that comprises a PilT N-terminus (PIN) domain of human SMG6,
wherein the RNA binding domain is at the amino terminus of the synthetic site-specific RNA endonuclease and the cleavage domain is at the carboxy terminus of the synthetic site-specific RNA endonuclease, and wherein the cleavage domain cleaves upstream and/or downstream of the eight-nucleotide target RNA,
under conditions whereby cleavage of the target mRNA occurs and wherein the RNA binding domain of the RNA endonuclease is modified to bind the target mRNA, thereby cleaving the target mRNA in the sample.
44 . A method of cleaving a target mRNA in a cell, comprising introducing into the cell a synthetic site-specific RNA endonuclease which comprises:
(i) an RNA binding protein domain that comprises a variant of the human Pumilio 1 homology domain, wherein said variant comprises eight 36-mer repeats, wherein each of the eight 36-mer repeats binds to a single nucleotide in an eight-nucleotide target RNA, wherein said eight-nucleotide target RNA comprises at least one cytosine, and wherein said variant comprises all of amino acids 828 to 1176 of SEQ ID NO:149 except for modifications at one or more positions corresponding to:
(a) positions 863 to 867 of SEQ ID NO:149,
(b) positions 899 to 903 of SEQ ID NO:149,
(c) positions 935 to 939 of SEQ ID NO:149,
(d) positions 971 to 975 of SEQ ID NO:149,
(e) positions 1007 to 1011 of SEQ ID NO:149,
(f) positions 1043 to 1047 of SEQ ID NO:149,
(g) positions 1079 to 1083 of SEQ ID NO:149, and/or
(h) positions 1122 to 1126 of SEQ ID NO:149,
wherein said modifications result in the variant comprising, in any combination, SerXXXGlu (SEQ ID NO:1) to bind guanine, (Cys/Ser)XXXGln (SEQ ID NO:66) to bind adenine, AsnXXXGln (SEQ ID NO:3) to bind uracil, and/or SerTyrXXArg (SEQ ID NO:4) to bind cytosine, wherein X is any amino acid;
(ii) a linker peptide; and
(iii) a cleavage domain that comprises a PilT N-terminus (PIN) domain of human SMG6,
wherein the RNA binding domain is at the amino terminus of the synthetic site-specific RNA endonuclease and the cleavage domain is at the carboxy terminus of the synthetic site-specific RNA endonuclease, and wherein the cleavage domain cleaves upstream and/or downstream of the eight-nucleotide target RNA,
wherein the RNA binding domain of the RNA endonuclease is modified to bind the target mRNA, under conditions whereby cleavage of the mRNA occurs, thereby cleaving the target mRNA in the cell.
45 . A method of inhibiting expression of a target gene in a cell, comprising introducing into the cell a synthetic site-specific RNA endonuclease which comprises:
(i) an RNA binding protein domain that comprises a variant of the human Pumilio 1 homology domain, wherein said variant comprises eight 36-mer repeats, wherein each of the eight 36-mer repeats binds to a single nucleotide in an eight-nucleotide target RNA, wherein said eight-nucleotide target RNA comprises at least one cytosine, and wherein said variant comprises all of amino acids 828 to 1176 of SEQ ID NO:149 except for modifications at one or more positions corresponding to:
(a) positions 863 to 867 of SEQ ID NO:149,
(b) positions 899 to 903 of SEQ ID NO:149,
(c) positions 935 to 939 of SEQ ID NO:149,
(d) positions 971 to 975 of SEQ ID NO:149,
(e) positions 1007 to 1011 of SEQ ID NO:149,
(f) positions 1043 to 1047 of SEQ ID NO:149,
(g) positions 1079 to 1083 of SEQ ID NO:149, and/or
(h) positions 1122 to 1126 of SEQ ID NO:149,
wherein said modifications result in the variant comprising, in any combination, SerXXXGlu (SEQ ID NO:1) to bind guanine, (Cys/Ser)XXXGln (SEQ ID NO:66) to bind adenine, AsnXXXGln (SEQ ID NO:3) to bind uracil, and/or SerTyrXXArg (SEQ ID NO:4) to bind cytosine, wherein X is any amino acid;
(ii) a linker peptide; and
(iii) a cleavage domain that comprises a PilT N-terminus (PIN) domain of human SMG6,
wherein the RNA binding domain is at the amino terminus of the synthetic site-specific RNA endonuclease and the cleavage domain is at the carboxy terminus of the synthetic site-specific RNA endonuclease, and wherein the cleavage domain cleaves upstream and/or downstream of the eight-nucleotide target RNA,
wherein the RNA binding domain of the RNA endonuclease is modified to bind mRNA encoding a gene product of the target gene, under conditions whereby cleavage of the mRNA occurs, thereby inhibiting expression of the target gene in the cell.
46 . The method of claim 45 , wherein the RNA endonuclease is introduced into the cell via a viral vector comprising a nucleotide sequence encoding the RNA endonuclease.
47 . The method of claim 46 , further comprising stably integrating the nucleotide sequence encoding the RNA endonuclease into the genome of the cell.
48 . The method of claim 45 , wherein the cell is in an organism.
49 . The method of claim 44 , wherein the RNA binding domain of the RNA endonuclease is modified to bind a target mRNA in a mitochondrion and wherein the RNA endonuclease comprises a mitochondrial targeting signal sequence.
50 . The method of claim 45 , wherein the RNA binding domain of the RNA endonuclease is modified to bind mRNA encoding a gene product of a target mitochondrial gene and wherein the RNA endonuclease comprises a mitochondrial targeting signal sequence.
51 . The method of claim 44 , wherein the RNA endonuclease is introduced into the cell via a viral vector comprising a nucleotide sequence encoding the RNA endonuclease.
52 . The method of claim 51 , further comprising stably integrating the nucleotide sequence encoding the RNA endonuclease into the genome of the cell.
53 . The method of claim 44 , wherein the cell is in an organism.
54 . The method of claim 49 , wherein the RNA endonuclease is introduced into the cell via a viral vector comprising a nucleotide sequence encoding the RNA endonuclease.
55 . The method of claim 54 , further comprising stably integrating the nucleotide sequence encoding the RNA endonuclease into the genome of the cell.
56 . The method of claim 49 , wherein the cell is in an organism.
57 . The method of claim 50 , wherein the RNA endonuclease is introduced into the cell via a viral vector comprising a nucleotide sequence encoding the RNA endonuclease.
58 . The method of claim 57 , further comprising stably integrating the nucleotide sequence encoding the RNA endonuclease into the genome of the cell.
59 . The method of claim 50 , wherein the cell is in an organism.Join the waitlist — get patent alerts
Track US2017137803A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.